Inhalok Airmaster

Fluticasone propionate, the active ingredient in Inhalok Airmaster, is a inhaled corticosteroid/long‑acting β2‑adrenergic agonist presented as a fixed‑dose inhalation formulation for inhalation use. It treats asthma and chronic obstructive pulmonary disease in adults and children.

GNH USA supplies Inhalok Airmaster as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU manufacturing standards for consistent quality. The company ensures regulatory compliance and reliable logistics for all markets.

Inhalok Airmaster combines fluticasone propionate and salmeterol to manage airway inflammation and bronchoconstriction in obstructive lung diseases.

Asthma: improves symptom control and reduces exacerbations. Chronic obstructive pulmonary disease (COPD): enhances lung function and lowers risk of flare‑ups. Severe asthma requiring combination therapy: provides both anti‑inflammatory and bronchodilator effects for patients not controlled on single agents.

The most frequently reported adverse reactions with Inhalok Airmaster are related to local airway irritation and systemic corticosteroid exposure.

Common Side Effects: - Oral thrush (candidiasis): mild fungal infection in the mouth. - Hoarseness or voice change: irritation of the vocal cords. - Cough or throat irritation: transient discomfort after inhalation. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Adrenal suppression: reduced cortisol production with prolonged use. - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.

Before prescribing Inhalok Airmaster, clinicians should consider several precautionary measures to minimize risks and ensure optimal therapy.

Rinse mouth after each inhalation: reduces risk of oral candidiasis. Monitor for signs of adrenal insufficiency: especially with high‑dose or prolonged use. Assess bone health periodically: long‑term corticosteroid exposure may affect bone density. Use with caution in patients with cardiovascular disease: β2‑agonists can affect heart rate. Avoid abrupt discontinuation: may lead to loss of asthma control. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Inhalok Airmaster may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase systemic corticosteroid levels. - Non‑selective β‑blockers (e.g., propranolol): diminish bronchodilator effect of salmeterol. - Concurrent use of other inhaled corticosteroids: heightens risk of systemic side effects.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may exacerbate hypokalemia caused by β2‑agonists. - Anticholinergic bronchodilators: additive bronchodilation may require dose adjustment. - MAO inhibitors: potential for enhanced cardiovascular effects.